TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07213804: FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinu

Sponsor: Eli Lilly and Company · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 1630 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$12,923,988

Rescue Site Savings

+$8,528,520

Unlock Full NCT07213804 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07213804 Rescue Dossier →